Heiko Enderling, Ph.D., FSMB

Peer-Reviewed Articles

1. Zahid MU, Waguespack M, Harman RC, Kercher EM, Nath S, Hasan T, Rizvi I, Spring BQ, Enderling H. Fractionated photoimmunotherapy stimulates an anti-tumour immune response: an integrated mathematical and in vitro study. Br J Cancer 131(8):1378-1386, 2024. PMID: 39261715.
2. Pasetto S, Harshe I, Brady-Nicholls R, Gatenby RA, Enderling H. Harnessing Flex Point Symmetry to Estimate Logistic Tumor Population Growth. Bull Math Biol 86(11):135, 2024. PMID: 39384633.
3. Pasetto S, Montejo M, Zahid MU, Rosa M, Gatenby R, Schlicke P, Diaz R, Enderling H. Calibrating tumor growth and invasion parameters with spectral spatial analysis of cancer biopsy tissues. NPJ Syst Biol Appl 10(1):112, 2024. PMID: 39358360.
4. Bekker RA, Obertopp N, Redler G, Penagaricano J, Caudell JJ, Yamoah K, Pilon-Thomas S, Moros EG, Enderling H. Spatially fractionated GRID radiation potentiates immune-mediated tumor control. Radiat Oncol 19(1):121, 2024. PMID: 39272128.
5. Kuznetsov VA, Enderling H, Chaplain M. Editorial: Mathematical modeling and computational predictions in oncoimmunology. Front Immunol 15:1432372, 2024. e-Pub 2024. PMID: 38873608.
6. Enderling H. Fractal calculus in tumor growth simulations: The proof is in the pudding. Biosystems 237:105141, 2024. e-Pub 2024. PMID: 38355079.
7. Browning AP, Lewin TD, Baker RE, Maini PK, Moros EG, Caudell J, Byrne HM, Enderling H. Correction to: Predicting Radiotherapy Patient Outcomes with Real-Time Clinical Data Using Mathematical Modelling. Bull Math Biol 86(4):35, 2024. e-Pub 2024. PMID: 38416252.
8. Mohsin N, Enderling H, Brady-Nicholls R, Zahid MU. Simulating tumor volume dynamics in response to radiotherapy: Implications of model selection. J Theor Biol 576:111656, 2024. e-Pub 2023. PMID: 37952611.
9. Browning AP, Lewin TD, Baker RE, Maini PK, Moros EG, Caudell J, Byrne HM, Enderling H. Predicting Radiotherapy Patient Outcomes with Real-Time Clinical Data Using Mathematical Modelling. Bull Math Biol 86(2):19, 2024. e-Pub 2024. PMID: 38238433.
10. Ravi H, Hawkins SH, Stringfield O, Pereira M, Chen DT, Enderling H, Michael Yu HH, Arrington JA, Sahebjam S, Raghunand N. Rules-based Volumetric Segmentation of Multiparametric MRI for Response Assessment in Recurrent High-Grade Glioma. Res Sq, 2023. e-Pub 2023. PMID: 37790451.
11. Pasetto S, Harshe I, Brady-Nicholls R, Gatenby RA, Enderling H. Logistic tumor-population growth and ghost-points symmetry. bioRxiv None(None):None, 2023. e-Pub 2023. PMID: 37693551.
12. Wilson N, Drapaca CS, Enderling H, Caudell JJ, Wilkie KP. Modelling Radiation Cancer Treatment with a Death-Rate Term in Ordinary and Fractional Differential Equations. Bull Math Biol 85(6):47, 2023. e-Pub 2023. PMID: 37186175.
13. Harshe I, Enderling H, Brady-Nicholls R. Predicting Patient-Specific Tumor Dynamics: How Many Measurements Are Necessary?. Cancers (Basel) 15(5), 2023. e-Pub 2023. PMID: 36900161.
14. Kutuva AR, Caudell JJ, Yamoah K, Enderling H, Zahid MU. Mathematical modeling of radiotherapy: impact of model selection on estimating minimum radiation dose for tumor control. Front Oncol 13:1130966, 2023. e-Pub 2023. PMID: 37901317.
15. Kirtane KS, Zahid MU, Enderling H, Harrison LB. Reimagining Cancer Staging in the Era of Evolutionary Oncology. J Natl Compr Canc Netw 20(12):1370-1372, 2022. PMID: 36509079.
16. Shyntar A, Patel A, Rhodes M, Enderling H, Hillen T. The Tumor Invasion Paradox in Cancer Stem Cell-Driven Solid Tumors. Bull Math Biol 84(12):139, 2022. e-Pub 2022. PMID: 36301402.
17. Brady-Nicholls R, Enderling H. Range-Bounded Adaptive Therapy in Metastatic Prostate Cancer. Cancers (Basel) 14(21), 2022. e-Pub 2022. PMID: 36358738.
18. Grass GD, Alfonso JCL, Welsh E, Ahmed KA, Teer JK, Pilon-Thomas S, Harrison LB, Cleveland JL, Mulé JJ, Eschrich SA, Enderling H, Torres-Roca JF. The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy. Int J Radiat Oncol Biol Phys 113(3):635-647, 2022. e-Pub 2022. PMID: 35289298.
19. Bekker RA, Zahid MU, Binning JM, Spring BQ, Hwu P, Pilon-Thomas S, Enderling H. Rethinking the immunotherapy numbers game. J Immunother Cancer 10(7), 2022. PMID: 35793871.
20. Buchsbaum JC, Jaffray DA, Ba D, Borkon LL, Chalk C, Chung C, Coleman MA, Coleman CN, Diehn M, Droegemeier KK, Enderling H, Espey MG, Greenspan EJ, Hartshorn CM, Hoang T, Hsiao HT, Keppel C, Moore NW, Prior F, Stahlberg EA, Tourassi G, Willcox KE. Predictive Radiation Oncology - A New NCI-DOE Scientific Space and Community. Radiat Res 197(4):434-445, 2022. PMID: 35090025.
21. Glazar DJ, Johnson M, Farinhas J, Steuer CE, Saba NF, Bonomi M, Chung CH, Enderling H. Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab. Oral Oncol 127:105787, 2022. e-Pub 2022. PMID: 35248922.
22. Enderling H. Mathematical oncology: A new frontier in cancer biology and clinical decision making: Comment on "Improving cancer treatments via dynamical biophysical models" by M. Kuznetsov, J. Clairambault & V. Volpert. Phys Life Rev 40:60-62, 2022. e-Pub 2021. PMID: 34857476.
23. Brüningk SC, Peacock J, Whelan CJ, Brady-Nicholls R, Yu HM, Sahebjam S, Enderling H. Author Correction: Intermittent radiotherapy as alternative treatment for recurrent high grade glioma: a modeling study based on longitudinal tumor measurements. Sci Rep 12(1):4441, 2022. e-Pub 2022. PMID: 35292722.
24. Ghaffari Laleh N, Loeffler CML, Grajek J, Stanková K, Pearson AT, Muti HS, Trautwein C, Enderling H, Poleszczuk J, Kather JN. Classical mathematical models for prediction of response to chemotherapy and immunotherapy. PLoS Comput Biol 18(2):e1009822, 2022. e-Pub 2022. PMID: 35120124.
25. Zahid MU, Mohamed ASR, Caudell JJ, Harrison LB, Fuller CD, Moros EG, Enderling H. Dynamics-Adapted Radiotherapy Dose (DARD) for Head and Neck Cancer Radiotherapy Dose Personalization. J Pers Med 11(11):None, 2021. e-Pub 2021. PMID: 34834476.
26. Zahid MU, Mohsin N, Mohamed ASR, Caudell JJ, Harrison LB, Fuller CD, Moros EG, Enderling H. Forecasting Individual Patient Response to Radiation Therapy in Head and Neck Cancer With a Dynamic Carrying Capacity Model. Int J Radiat Oncol Biol Phys 111(3):693-704, 2021. e-Pub 2021. PMID: 34102299.
27. Pasetto S, Enderling H, Gatenby RA, Brady-Nicholls R. Intermittent Hormone Therapy Models Analysis and Bayesian Model Comparison for Prostate Cancer. Bull Math Biol 84(1):2, 2021. e-Pub 2021. PMID: 34797430.
28. Alfonso JCL, Grass GD, Welsh E, Ahmed KA, Teer JK, Pilon-Thomas S, Harrison LB, Cleveland JL, Mulé JJ, Eschrich SA, Torres-Roca JF, Enderling H. Tumor-immune ecosystem dynamics define an individual Radiation Immune Score to predict pan-cancer radiocurability. Neoplasia 23(11):1110-1122, 2021. e-Pub 2021. PMID: 34619428.
29. Brüningk SC, Peacock J, Whelan CJ, Brady-Nicholls R, Yu HM, Sahebjam S, Enderling H. Intermittent radiotherapy as alternative treatment for recurrent high grade glioma: a modeling study based on longitudinal tumor measurements. Sci Rep 11(1):20219, 2021. e-Pub 2021. PMID: 34642366.
30. Brady-Nicholls R, Zhang J, Zhang T, Wang AZ, Butler R, Gatenby RA, Enderling H. Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics. Neoplasia 23(9):851-858, 2021. e-Pub 2021. PMID: 34298234.
31. Miller, AK, Brown, JS, Enderling, H, Basanta, D, Whelan, CJ. The Evolutionary Ecology of Dormancy in Nature and in Cancer. Frontiers in Ecology and Evolution 9, 2021. PMID: None.
32. Liu J, Hormuth DA, Davis T, Yang J, McKenna MT, Jarrett AM, Enderling H, Brock A, Yankeelov TE. A time-resolved experimental-mathematical model for predicting the response of glioma cells to single-dose radiation therapy. Integr Biol (Camb) 13(7):167-183, 2021. PMID: 34060613.
33. Pasetto S, Gatenby RA, Enderling H. Bayesian Framework to Augment Tumor Board Decision Making. JCO Clin Cancer Inform 5:508-517, 2021. PMID: 33974446.
34. Sahebjam S, Forsyth PA, Tran ND, Arrington JA, Macaulay R, Etame AB, Walko CM, Boyle T, Peguero EN, Jaglal M, Mokhtari S, Enderling H, Raghunand N, Gatewood T, Long W, Dzierzeski JL, Evernden B, Robinson T, Wicklund MC, Kim S, Thompson ZJ, Chen DT, Chinnaiyan P, Yu HM. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study. Neuro Oncol 23(4):677-686, 2021. PMID: 33173935.
35. Tomaszewski MR, Dominguez-Viqueira W, Ortiz A, Shi Y, Costello JR, Enderling H, Rosenberg SA, Gillies RJ. Heterogeneity analysis of MRI T2 maps for measurement of early tumor response to radiotherapy. NMR Biomed 34(3):e4454, 2021. e-Pub 2020. PMID: 33325086.
36. Walker SA, Pham A, Nizzero S, Kim M, Riter B, Bletz J, Judge S, Phillips B, Noble D, Murray D, Wetzel E, Samson S, McMahon M, Flink C, Couch J, Tomlin C, Swanson K, Anderson ARA, Odde D, Shen H, Hughes S, Zahir N, Enderling H, Wolfram J. Education and Outreach in Physical Sciences in Oncology. Trends Cancer 7(1):3-9, 2021. e-Pub 2020. PMID: 33168416.
37. Enderling H, Wolkenhauer O. Are all models wrong?. Comput Syst Oncol 1(1), 2020. e-Pub 2021. PMID: 33585835.
38. Enderling H, Altrock PM, Andor N, Basanta D, Brown JS, Gatenby RA, Marusyk A, Rejniak KA, Silva A, Anderson ARA. High School Internship Program in Integrated Mathematical Oncology (HIP IMO): Five-Year Experience at Moffitt Cancer Center. Bull Math Biol 82(7):91, 2020. e-Pub 2020. PMID: 32648152.
39. Glazar DJ, Grass GD, Arrington JA, Forsyth PA, Raghunand N, Yu HM, Sahebjam S, Enderling H. Tumor Volume Dynamics as an Early Biomarker for Patient-Specific Evolution of Resistance and Progression in Recurrent High-Grade Glioma. J Clin Med 9(7):None, 2020. e-Pub 2020. PMID: 32605050.
40. Enderling H. Re: Numerical simulation of normal and cancer cells' populations with fractional derivative under radiotherapy. Comput Methods Programs Biomed 188(None):105417, 2020. e-Pub 2020. PMID: 32131982.
41. Aherne NJ, Dhawan A, Scott JG, Enderling H. Mathematical oncology and it's application in non melanoma skin cancer - A primer for radiation oncology professionals. Oral Oncol 103(None):104473, 2020. e-Pub 2020. PMID: 32109841.
42. Brady-Nicholls R, Nagy JD, Gerke TA, Zhang T, Wang AZ, Zhang J, Gatenby RA, Enderling H. Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation. Nat Commun 11(1):1750, 2020. e-Pub 2020. PMID: 32273504.
43. Lewin TD, Byrne HM, Maini PK, Caudell JJ, Moros EG, Enderling H. The importance of dead material within a tumour on the dynamics in response to radiotherapy. Phys Med Biol 65(1):015007, 2020. e-Pub 2020. PMID: 31593931.
44. Heidbuechel JPW, Abate-Daga D, Engeland CE, Enderling H. Mathematical Modeling of Oncolytic Virotherapy. Methods Mol Biol 2058(None):307-320, 2020. PMID: 31486048.
45. Sunassee ED, Tan D, Ji N, Brady R, Moros EG, Caudell JJ, Yartsev S, Enderling H. Proliferation saturation index in an adaptive Bayesian approach to predict patient-specific radiotherapy responses. Int J Radiat Biol 95(10):1421-1426, 2019. e-Pub 2019. PMID: 30831050.
46. Brady R, Enderling H. Mathematical Models of Cancer: When to Predict Novel Therapies, and When Not to. Bull Math Biol 81(10):3722-3731, 2019. e-Pub 2019. PMID: 31338741.
47. Schacht C, Meade A, Banks HT, Enderling H, Abate-Daga D. Estimation of probability distributions of parameters using aggregate population data: analysis of a CAR T-cell cancer model. Math Biosci Eng 16(6):7299-7326, 2019. PMID: 31698614.
48. Ferrall-Fairbanks MC, Glazar DJ, Brady RJ, Kimmel GJ, Zahid MU, Altrock PM, Enderling H. Re: Simulation analysis for tumor radiotherapy based on three-component mathematical models. J Appl Clin Med Phys 20(7):204-205, 2019. e-Pub 2019. PMID: 31145529.
49. Walker R, Mejia J, Lee JK, Pimiento JM, Malafa M, Giuliano AR, Coppola D, Enderling H. Personalizing Gastric Cancer Screening With Predictive Modeling of Disease Progression Biomarkers. Appl Immunohistochem Mol Morphol 27(4):270-277, 2019. PMID: 29084052.
50. Spring BQ, Lang RT, Kercher EM, Rizvi I, Wenham RM, Conejo-Garcia JR, Hasan T, Gatenby RA, Enderling H. Illuminating the Numbers: Integrating Mathematical Models to Optimize Photomedicine Dosimetry and Combination Therapies. Front Phys 7(None):None, 2019. e-Pub 2019. PMID: 31123672.
51. López Alfonso JC, Poleszczuk J, Walker R, Kim S, Pilon-Thomas S, Conejo-Garcia JJ, Soliman H, Czerniecki B, Harrison LB, Enderling H. Immunologic Consequences of Sequencing Cancer Radiotherapy and Surgery. JCO Clin Cancer Inform 3(None):1-16, 2019. PMID: 30964698.
52. Poleszczuk J, Enderling H. The Optimal Radiation Dose to Induce Robust Systemic Anti-Tumor Immunity. Int J Mol Sci 19(11):None, 2018. e-Pub 2018. PMID: 30380596.
53. Okunieff P, Casey-Sawicki K, Lockney NA, Hoppe BS, Enderling H, Pinnix C, Welsh J, Krishnan S, Yothers G, Brown M, Knox S, Bristow R, Spellman P, Mitin T, Nabavizadeh N, Jaboin J, Manning HC, Feng F, Galbraith S, Solanki AA, Harkenrider MM, Tuli R, Decker RH, Finkelstein SE, Hsu CC, Ha CS, Jagsi R, Shumway D, Daly M, Wang TJC, Fitzgerald TJ, Laurie F, Marshall DT, Raben D, Constine L, Thomas CR, Kachnic LA. Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017. Clin Cancer Res 24(15):3500-3509, 2018. e-Pub 2018. PMID: 29661779.
54. Howard R, Al Diffalha S, Pimiento J, Mejia J, Enderling H, Giuliano A, Coppola D. CD133 Expression as a Helicobacter pylori-independent Biomarker of Gastric Cancer Progression. Anticancer Res 38(8):4443-4448, 2018. PMID: 30061208.
55. López Alfonso JC, Parsai S, Joshi N, Godley A, Shah C, Koyfman SA, Caudell JJ, Fuller CD, Enderling H, Scott JG. Temporally feathered intensity-modulated radiation therapy: A planning technique to reduce normal tissue toxicity. Med Phys 45(7):3466-3474, 2018. e-Pub 2018. PMID: 29786861.
56. Walker R, Poleszczuk J, Pilon-Thomas S, Kim S, AARA A, Czerniecki BJ, Harrison LB, Moros EG, Enderling H. Immune interconnectivity of anatomically distant tumors as a potential mediator of systemic responses to local therapy. Sci Rep 8(1):9474, 2018. e-Pub 2018. PMID: 29930290.
57. Lewin TD, Maini PK, Moros EG, Enderling H, Byrne HM. The Evolution of Tumour Composition During Fractionated Radiotherapy: Implications for Outcome. Bull Math Biol 80(5):1207-1235, 2018. e-Pub 2018. PMID: 29488054.
58. Poleszczuk J, Walker R, Moros EG, Latifi K, Caudell JJ, Enderling H. Predicting Patient-Specific Radiotherapy Protocols Based on Mathematical Model Choice for Proliferation Saturation Index. Bull Math Biol 80(5):1195-1206, 2018. e-Pub 2017. PMID: 28681150.
59. Walker R, Poleszczuk J, Mejia J, Lee JK, Pimiento JM, Malafa M, Giuliano AR, Enderling H, Coppola D. Toward early detection of Helicobacter pylori-associated gastric cancer. Gastric Cancer 21(2):196-203, 2018. e-Pub 2017. PMID: 28725964.
60. Forouzannia F, Enderling H, Kohandel M. Mathematical Modeling of the Effects of Tumor Heterogeneity on the Efficiency of Radiation Treatment Schedule. Bull Math Biol 80(2):283-293, 2018. e-Pub 2017. PMID: 29218592.
61. Walker R, Schoenfeld JD, Pilon-Thomas S, Poleszczuk J, Enderling H. Evaluating the potential for maximized T cell redistribution entropy to improve abscopal responses to radiotherapy. Converg Sci Phys Oncol 3(3):None, 2017. e-Pub 2017. PMID: 29774168.
62. Shiao JC, Mohamed ASR, Messer JA, Hutcheson KA, Johnson JM, Enderling H, Kamal M, Warren BW, Pham B, Morrison WH, Zafereo ME, Hessel AC, Lai SY, Kies MS, Ferrarotto R, Garden AS, Schomer DF, Gunn GB, Phan J, Frank SJ, Beadle BM, Weber RS, Lewin JS, Rosenthal DI, Fuller CD. Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. Head Neck 39(8):1609-1620, 2017. e-Pub 2017. PMID: 28464542.
63. Sasi SP, Yan X, Zuriaga-Herrero M, Gee H, Lee J, Mehrzad R, Song J, Onufrak J, Morgan J, Enderling H, Walsh K, Kishore R, Goukassian DA. Different Sequences of Fractionated Low-Dose Proton and Single Iron-Radiation-Induced Divergent Biological Responses in the Heart. Radiat Res 188(2):191-203, 2017. e-Pub 2017. PMID: 28613990.
64. Poleszczuk J, Luddy K, Chen L, Lee JK, Harrison LB, Czerniecki BJ, Soliman H, Enderling H. Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival. Breast Cancer Res 19(1):75, 2017. e-Pub 2017. PMID: 28666457.
65. Perni S, Mohamed AS, Scott J, Enderling H, Garden AS, Gunn GB, Rosenthal DI, Fuller CD. CT-based volumetric tumor growth velocity: A novel imaging prognostic indicator in oropharyngeal cancer patients receiving radiotherapy. Oral Oncol 63:16-22, 2016. e-Pub 2016. PMID: 27938995.
66. Poleszczuk JT, Johnstone PA, Enderling H. Stratifying prostate cancer patients by relative lymph node involvement: population- and modeling-based study. Cancer Med 5(8):1850-5, 2016. e-Pub 2016. PMID: 27227813.
67. Poleszczuk JT, Luddy KA, Prokopiou S, Robertson-Tessi M, Moros EG, Fishman M, Djeu JY, Finkelstein SE, Enderling H. Abscopal Benefits of Localized Radiotherapy Depend on Activated T-cell Trafficking and Distribution between Metastatic Lesions. Cancer Res 76(5):1009-18, 2016. e-Pub 2016. PMID: 26833128.
68. Sasi SP, Park D, Muralidharan S, Wage J, Kiladjian A, Onufrak J, Enderling H, Yan X, Goukassian DA. Corrigendum to "Particle Radiation-Induced Nontargeted Effects in Bone-Marrow-Derived Endothelial Progenitor Cells". Stem Cells Int 2016(None):7958361, 2016. e-Pub 2016. PMID: 26880990.
69. Poleszczuk J, Enderling H. Cancer Stem Cell Plasticity as Tumor Growth Promoter and Catalyst of Population Collapse. Stem Cells Int 2016(None):3923527, 2016. e-Pub 2015. PMID: 26858759.
70. Poleszczuk J, Macklin P, Enderling H. Agent-Based Modeling of Cancer Stem Cell Driven Solid Tumor Growth. Methods Mol Biol 1516(None):335-346, 2016. PMID: 27044046.
71. Sasi SP, Song J, Park D, Enderling H, McDonald JT, Gee H, Garrity B, Shtifman A, Yan X, Walsh K, Natarajan M, Kishore R, Goukassian DA. TNF-TNFR2/p75 signaling inhibits early and increases delayed nontargeted effects in bone marrow-derived endothelial progenitor cells. J Biol Chem 290(45):27014, 2015. PMID: 26546693.
72. Prokopiou S, Moros EG, Poleszczuk J, Caudell J, Torres-Roca JF, Latifi K, Lee JK, Myerson R, Harrison LB, Enderling H. A proliferation saturation index to predict radiation response and personalize radiotherapy fractionation. Radiat Oncol 10(None):159, 2015. e-Pub 2015. PMID: 26227259.
73. Johnstone PA, Enderling H. Mathematical Modeling of Acupuncture as Cancer Symptom Therapy: First Steps. J Acupunct Meridian Stud 8(3):113-4, 2015. e-Pub 2015. PMID: 26100063.
74. Poleszczuk J, Hahnfeldt P, Enderling H. Evolution and phenotypic selection of cancer stem cells. PLoS Comput Biol 11(3):e1004025, 2015. e-Pub 2015. PMID: 25742563.
75. Sasi SP, Park D, Muralidharan S, Wage J, Kiladjian A, Onufrak J, Enderling H, Yan X, Goukassian DA. Particle Radiation-Induced Nontargeted Effects in Bone-Marrow-Derived Endothelial Progenitor Cells. Stem Cells Int 2015(None):496512, 2015. e-Pub 2015. PMID: 26074973.
76. Yan X, Sasi SP, Gee H, Lee J, Yang Y, Mehrzad R, Onufrak J, Song J, Enderling H, Agarwal A, Rahimi L, Morgan J, Wilson PF, Carrozza J, Walsh K, Kishore R, Goukassian DA. Correction: Cardiovascular Risks Associated with Low Dose Ionizing Particle Radiation. PLoS One 10(11):e0142764, 2015. e-Pub 2015. PMID: 26544605.
77. Poleszczuk J, Hahnfeldt P, Enderling H. Therapeutic implications from sensitivity analysis of tumor angiogenesis models. PLoS One 10(3):e0120007, 2015. e-Pub 2015. PMID: 25785600.
78. Sasi SP, Bae S, Song J, Perepletchikov A, Schneider D, Carrozza J, Yan X, Kishore R, Enderling H, Goukassian DA. Correction: Therapeutic Non-Toxic Doses of TNF Induce Significant Regression in TNFR2-p75 Knockdown Lewis Lung Carcinoma Tumor Implants. PLoS One 10(11):e0144213, 2015. e-Pub 2015. PMID: 26619137.
79. Weekes SL, Barker B, Bober S, Cisneros K, Cline J, Thompson A, Hlatky L, Hahnfeldt P, Enderling H. A multicompartment mathematical model of cancer stem cell-driven tumor growth dynamics. Bull Math Biol 76(7):1762-82, 2014. e-Pub 2014. PMID: 24840956.
80. Poleszczuk J, Hahnfeldt P, Enderling H. Biphasic modulation of cancer stem cell-driven solid tumour dynamics in response to reactivated replicative senescence. Cell Prolif 47(3):267-76, 2014. e-Pub 2014. PMID: 24666838.
81. Sasi SP, Song J, Park D, Enderling H, McDonald JT, Gee H, Garrity B, Shtifman A, Yan X, Walsh K, Natarajan M, Kishore R, Goukassian DA. TNF-TNFR2/p75 signaling inhibits early and increases delayed nontargeted effects in bone marrow-derived endothelial progenitor cells. J Biol Chem 289(20):14178-93, 2014. e-Pub 2014. PMID: 24711449.
82. Poleszczuk J, Enderling H. A High-Performance Cellular Automaton Model of Tumor Growth with Dynamically Growing Domains. Appl Math (Irvine) 5(1):144-152, 2014. PMID: 25346862.
83. Yan X, Sasi SP, Gee H, Lee J, Yang Y, Mehrzad R, Onufrak J, Song J, Enderling H, Agarwal A, Rahimi L, Morgan J, Wilson PF, Carrozza J, Walsh K, Kishore R, Goukassian DA. Cardiovascular risks associated with low dose ionizing particle radiation. PLoS One 9(10):e110269, 2014. e-Pub 2014. PMID: 25337914.
84. Sasi SP, Bae S, Song J, Perepletchikov A, Schneider D, Carrozza J, Yan X, Kishore R, Enderling H, Goukassian DA. Therapeutic non-toxic doses of TNF induce significant regression in TNFR2-p75 knockdown Lewis lung carcinoma tumor implants. PLoS One 9(3):e92373, 2014. e-Pub 2014. PMID: 24664144.
85. McGuire MF, Enderling H, Wallace DI, Batra J, Jordan M, Kumar S, Panetta JC, Pasquier E. Formalizing an integrative, multidisciplinary cancer therapy discovery workflow. Cancer Res 73(20):6111-7, 2013. e-Pub 2013. PMID: 23955390.
86. Gao X, McDonald JT, Hlatky L, Enderling H. Acute and fractionated irradiation differentially modulate glioma stem cell division kinetics. Cancer Res 73(5):1481-90, 2013. e-Pub 2012. PMID: 23269274.
87. Hillen T, Enderling H, Hahnfeldt P. The tumor growth paradox and immune system-mediated selection for cancer stem cells. Bull Math Biol 75(1):161-84, 2013. e-Pub 2012. PMID: 23196354.
88. Enderling H, Hlatky L, Hahnfeldt P. Cancer Stem Cells: A Minor Cancer Subpopulation that Redefines Global Cancer Features. Front Oncol 3:76, 2013. e-Pub 2013. PMID: 23596563.
89. Enderling H. Cancer stem cells and tumor dormancy. Adv Exp Med Biol 734(None):55-71, 2013. PMID: 23143975.
90. Enderling H. Unveiling stem cell kinetics: prime time for integrating experimental and computational models. Front Oncol 3(None):291, 2013. e-Pub 2013. PMID: 24350056.
91. Enderling H, Rejniak KA. Simulating cancer: computational models in oncology. Front Oncol 3:233, 2013. e-Pub 2013. PMID: 24062986.
92. Sasi SP, Yan X, Enderling H, Park D, Gilbert HY, Curry C, Coleman C, Hlatky L, Qin G, Kishore R, Goukassian DA. Breaking the 'harmony' of TNF-α signaling for cancer treatment. Oncogene 31(37):4117-27, 2012. e-Pub 2011. PMID: 22158049.
93. Enderling H, Hlatky L, Hahnfeldt P. Immunoediting: evidence of the multifaceted role of the immune system in self-metastatic tumor growth. Theor Biol Med Model 9:31, 2012. e-Pub 2012. PMID: 22838395.
94. Enderling H, Hahnfeldt P, Hlatky L, Almog N. Systems biology of tumor dormancy: linking biology and mathematics on multiple scales to improve cancer therapy. Cancer Res 72(9):2172-5, 2012. e-Pub 2012. PMID: 22414579.
95. Enderling H, Hlatky L, Hahnfeldt P. The promoting role of a tumour-secreted chemorepellent in self-metastatic tumour progression. Math Med Biol 29(1):21-9, 2012. e-Pub 2010. PMID: 20929852.
96. Morton CI, Hlatky L, Hahnfeldt P, Enderling H. Non-stem cancer cell kinetics modulate solid tumor progression. Theor Biol Med Model 8(None):48, 2011. e-Pub 2011. PMID: 22208390.
97. Enderling H, Hahnfeldt P. Cancer stem cells in solid tumors: is 'evading apoptosis' a hallmark of cancer?. Prog Biophys Mol Biol 106(2):391-9, 2011. e-Pub 2011. PMID: 21473880.
98. Tang J, Enderling H, Becker-Weimann S, Pham C, Polyzos A, Chen CY, Costes SV. Phenotypic transition maps of 3D breast acini obtained by imaging-guided agent-based modeling. Integr Biol (Camb) 3(4):408-21, 2011. e-Pub 2011. PMID: 21373705.
99. Enderling H, Chaplain MA, Hahnfeldt P. Quantitative modeling of tumor dynamics and radiotherapy. Acta Biotheor 58(4):341-53, 2010. e-Pub 2010. PMID: 20658170.
100. Enderling H, Hlatky L, Hahnfeldt P. Tumor morphological evolution: directed migration and gain and loss of the self-metastatic phenotype. Biol Direct 5(None):23, 2010. e-Pub 2010. PMID: 20406441.
101. Enderling H, Anderson AR, Chaplain MA, Beheshti A, Hlatky L, Hahnfeldt P. Paradoxical dependencies of tumor dormancy and progression on basic cell kinetics. Cancer Res 69(22):8814-21, 2009. e-Pub 2009. PMID: 19887613.
102. Enderling H, Hlatky L, Hahnfeldt P. Migration rules: tumours are conglomerates of self-metastases. Br J Cancer 100(12):1917-25, 2009. e-Pub 2009. PMID: 19455139.
103. Enderling H, Alexander NR, Clark ES, Branch KM, Estrada L, Crooke C, Jourquin J, Lobdell N, Zaman MH, Guelcher SA, Anderson AR, Weaver AM. Dependence of invadopodia function on collagen fiber spacing and cross-linking: computational modeling and experimental evidence. Biophys J 95(5):2203-18, 2008. e-Pub 2008. PMID: 18515372.
104. Enderling H, Chaplain MA, Anderson AR, Vaidya JS. A mathematical model of breast cancer development, local treatment and recurrence. J Theor Biol 246(2):245-59, 2007. e-Pub 2006. PMID: 17289081.
105. Enderling H, Anderson AR, Chaplain MA, Rowe GW. Visualisation of the numerical solution of partial differential equation systems in three space dimensions and its importance for mathematical models in biology. Math Biosci Eng 3(4):571-82, 2006. PMID: 20361833.
106. Enderling H, Anderson AR, Chaplain MA, Munro AJ, Vaidya JS. Mathematical modelling of radiotherapy strategies for early breast cancer. J Theor Biol 241(1):158-71, 2006. e-Pub 2005. PMID: 16386275.

Other Articles

1. Bekker RA, Kim S, Pilon-Thomas S, Enderling H Mathematical modeling of radiotherapy and its impact on tumor interactions with the immune system. Neoplasia 28:100796, 2022. PMID: 35447601.
2. Enderling H, Alfonso JCL, Moros E, Caudell JJ, Harrison LB Integrating Mathematical Modeling into the Roadmap for Personalized Adaptive Radiation Therapy. Trends Cancer 5(8):467-474, 2019. PMID: 31421904.
3. Rockne RC, Hawkins-Daarud A, Swanson KR, Sluka JP, Glazier JA, Macklin P, Hormuth DA, Jarrett AM, EABF L, Tinsley Oden J, Biros G, Yankeelov TE, Curtius K, Al Bakir I, Wodarz D, Komarova N, Aparicio L, Bordyuh M, Rabadan R, Finley SD, Enderling H, Caudell J, Moros EG, Anderson ARA, Gatenby RA, Kaznatcheev A, Jeavons P, Krishnan N, Pelesko J, Wadhwa RR, Yoon N, Nichol D, Marusyk A, Hinczewski M, Scott JG The 2019 mathematical oncology roadmap. Phys Biol 16(4):041005, 2019. PMID: 30991381.
4. Santiago DN, Heidbuechel JPW, Kandell WM, Walker R, Djeu J, Engeland CE, Abate-Daga D, Enderling H Fighting Cancer with Mathematics and Viruses. Viruses 9(9):None, 2017. PMID: 28832539.
5. Caudell JJ, Torres-Roca JF, Gillies RJ, Enderling H, Kim S, Rishi A, Moros EG, Harrison LB The future of personalised radiotherapy for head and neck cancer. Lancet Oncol 18(5):e266-e273, 2017. PMID: 28456586.
6. Walker R, Enderling H From concept to clinic: Mathematically informed immunotherapy. Curr Probl Cancer 40(1):68-83, 2016. PMID: 26645497.
7. Enderling H Cancer stem cells: small subpopulation or evolving fraction?. Integr Biol (Camb) 7(1):14-23, 2015. PMID: 25359461.
8. Enderling H, Chaplain MA Mathematical modeling of tumor growth and treatment. Curr Pharm Des 20(30):4934-40, 2014. PMID: 24283955.

Abstracts

1. Enderling H. 3579: Digital twins for personalised radiation oncology. Radiotherapy and Oncology 194(None):S135, 2024. PMID: None.
2. Scott E, Zahid MU, Caudell JJ, Torres-Roca JF, Enderling H. Adaptive Radiation Fractionation in Head and Neck Cancer through Modeling Tumor Volume Dynamics. International Journal of Radiation Oncology, Biology, Physics 120(2):e655-e656, 2024. PMID: None.
3. Obertopp N, Thomas A, Ali J, Blauvelt J, Hall A, Enderling H, Pilon-Thomas S. P12. 01 Utilizing radiation to improve adoptive cell therapy with tumor infiltrating lymphocytes. Journal of ImmunoTherapy of Cancer 11(S1):A1076, 2024. PMID: None.
4. Pandit S, Enderling H. 969 Patient-specific immune cell radiosensitivity ratio necessary for predicting radiotherapy outcomes in lung cancer: a mathematical modeling study. Journal for ImmunoTherapy of Cancer 12(S1):A30, 2023. PMID: None.
5. Zahid MU, Yang GQ, Echevarria M, Caudell JJ, Enderling H. Proliferation Saturation Index to Simulate Adaptive Radiation Fractionation in HPV-Associated Oropharyngeal Cancer. International Journal of Radiation Oncology, Biology, Physics 117(2):e459-e496, 2023. PMID: None.
6. Caudell J, Echevarria M, Yang G, Kim Y, Kish J, Muzaffar J, Chung C, Enderling H. OC-0106 Prospective Trial of Personalized Fractionation in Low-risk HPV Positive Oropharyngeal Cancerroph. Radiotherapy and Oncology 182(None):S67-S68, 2023. PMID: None.
7. Robertson-Tessi M, Brown J, Poole M, Luddy K, Marusyk A, Gallaher J, West J, Johnson M, Enderling H, Makanji R, Farinhas J, Gatenby R, Reed D, Chung C, Anderson A. Evolutionary Tumor Board: Implementing dynamic personalized therapy using evolutionary theory and mathematical modeling for clinical decision support. None 82(10 Supplement):None, 2022. PMID: None.
8. Brady-Nicholls R, Enderling H. Exploring how competition can be leveraged to improve adaptive therapy in metastatic prostate cancer. None 82(10 Supplement):None, 2022. PMID: None.
9. Bhandari M, Zhang G, Oliver D, Graham J, Enderling H, Sahebjam S, Yu HH. Correlation of Various Dosimetric and Volumetric Parameters with Time to Tumor Progression in Recurrent Gliblastoma Patients. American Journal of Clinical Oncology-Cancer Clinical Trials 45(9):S55-S56, 2022. PMID: None.
10. Pasetto S, Zahid M, Diaz R, Rosa M, Gatenby R, Enderling H. Breast cancer patient-specific reaction-diffusion from spatial spectral analysis of immunohistochemistry slides. Med. Phys 49(6):E804, 2022. PMID: None.
11. Enderling H, Zahid M, Moros E, Caudell J, Mohamed A, Fuller C. Personalization of Patient Specific Radiation Dose and Dose Fractionation Using Volumetric Tumor Dynamics. Med. Phys 49(6):E676-E676, 2022. PMID: None.
12. Zahid MU, Caudell JJ, Moros EG, Mohamed AS, Fuller CD, Harrison LB, Enderling H. In Silico Trial to Estimate Personalized RT Dose in Head and Neck Cancer. None 111(3 Supplement):E146-E147, 2021. PMID: None.
13. Brady R, Enderling H. Using PSA dynamics to forecast individual responses to intermittent androgen deprivation. None 26(11 Supplement):None, 2020. PMID: None.
14. Zahid MU, Mohsin N, Mohamed AS, Caudell JJ, Harrison LB, Fuller CD, Moros EG, Enderling H. Forecasting individual patient response to radiotherapy with a dynamic carrying capacity model. Med. Phys 47(6):E423, 2020. PMID: None.
15. Glazar D, Brady R, Howard R, Grass D, Arrington J, Yu M, Raghunanad N, Sahebjam S, Enderling H. Early tumor volume evolution adaptively predicts patient-specific response and progression risk to radiotherapy, pembrolizumab, and bevacizumab in recurrent high-grae glioma in phase 1 trail. None 21(Supplement 6):63-64, 2019. PMID: None.
16. Zahid M, Glazar D, Brady R, Moros EG, Harrison LB, Caudell JJ, Enderling H. Proliferation Saturation Index to Prospectively Predict Patient-Specific Responses to Radiation in Oropharyngeal Cancer. None 105(1 Supplement):E792, 2019. PMID: None.
17. Grass GD, Alfonso JCL, Welsh E, Ahmed KA, Harrison LB, Eschrich SA, Enderling H. Modeling Variability in Radiosensitivity and Tumor Immune Contexture to Personalize Radiotherapy. None 105(1 Supplement):S123-S124, 2019. PMID: None.
18. Brady R, Enderling H. Using PSA dynamics to predict patient-specific responses to intermittent androgen deprivation. None 79(13 Supplement):None, 2019. PMID: None.
19. Sheng K, Wang A, Enderling H. Optimization in imaging and therapy. Med Phys 46(6):E284, 2019. PMID: None.
20. Parsai S, Donaghue JD, Alfonso JCL, Joshi NP, Godley AR, Caudell JJ, Fuller CD, Enderling H, Koyfman S, Scott JG. Feasibility of Temporally Feathered Intensity Modulated Radiation Therapy Plans: Techniques to Reduce Normal Tissue Toxicity. None 102(3 Supplement):E530, 2018. PMID: None.
21. Brady R, Nagy J, Enderling H. Simulating prostate cancer stem cell dynamics to predict patient-specific sensitivity or resistance to intermittent androgen-deprivation therapy. None 78(16 Supplement):None, 2018. PMID: None.
22. Heidbuechel JPW, Speck T, Vainalde R, Abate-Daga D, Santiago DN, Enderling H, Ball CR, Jaeger D, von Kalle C, Ungerechts G, Engeland CE. Oncolytic viruses to enhance BiTE and CAR therapy of solid tumors. Mol. Ther 26(5):9-10, 2018. PMID: None.
23. Rishi A, Latifi K, Naghavi AO, Zhang GG, Enderling H, Moros EG, Heukelom J, Mohamed ASR, Fuller CD, Harrison LB, Caudell JJ. CT-based nodal radiomics features and outcome in head and neck squamous cell carcinoma 99(2 Supplement):E715, 2017. PMID: None.
24. Chou KT, Grass GD, Zhang GG, Latifi K, Arrington J, Sabhemjam S, Raghunand N, Enderling H, Stringfield O, Sarangkasiri S, Forsyth P, Johnstone PAS, Robinson TJ, Yu HHM. Pretreatment T2-Weighted Fluid Attenuated Inversion Recovery (T2-FLAIRpre) MRI May Improve Gross Tumor Volume Delineation for Recurrent Glioblastoma Treated with Salvage Hypofractionated Stereotactic Radiation Therapy 99(2 Supplement):E650, 2017. PMID: None.
25. Enderling H, Latifi K, Rishi A, Howard R, Moros EG, Heukelom J, Mohamed ASR, Fuller CD, Harrison LB, Caudell JJ. Mathematical Model of Head and Neck Cancer Response to Predict Fractionation Schema for Robust Responses During Radiation Therapy. None 99(2 Supplement):E656, 2017. PMID: None.
26. Latifi K, Rishi A, Enderling H, Moros EG, Heukelom J, Mohamed ASR, Fuller CD, Harrison LB, Caudell JJ. Mid-treatment Nodal Response is Associated with Outcome in Head and Neck Squamous Cell Cancer 99(2 Supplment), 2017. PMID: None.
27. Enderling H, Walker R, Pimiento J, Mejia J, Coppola D. Computational modeling to suggest patient-specific screening schedules for early detection of gastric cancer. None 77(13 Supplement):None, 2017. PMID: None.
28. Walker R, Poleszczuk J, Enderling H. Local and systemic tumor-immune dynamics in metastatic cancer. None 77(13 Supplement):None, 2017. PMID: None.
29. Enderling H. Local and systemic tumor immune dynamics. Bulletin of the American Physical Society 62(None):None, 2017. PMID: None.
30. Poleszczuk J, Luddy K, Pilon-Thomas S, Schoenfeld J, Enderling H. Personalizing the synergy of focal radiation and immunotherapy. None 76(14 Supplement):None, 2016. PMID: None.
31. Walker R, Mejia J, Enderling H, Pimiento JM, Coppola D. Cross-disciplinary methods for personalizing screening modalities for early gastric cancer intervention. None 76(14 Supplement):None, 2016. PMID: None.
32. Walker R, Mejia J, Enderling H, Pimiento JM, Malafa M, Coppola D. CD44, CD133 and Lgr5 as biomarkers for early detection of H. pylori-associated gastric cancer. None 30(S1):696.4, 2016. PMID: None.
33. Lewin T, Kim J, Latifi K, Poleszczuk J, Bull J, Byrne H, Torres-Roca JF, Moros EG, Gatenby R, Harrison LB, Heukelom J, Mohamed ASR, Rosenthal DI, Fuller CD, Caudell JJ, Enderling H. Proliferation Saturation Index Predicts Oropharyngeal Squamous Cell Cancer Gross Tumor Volume Reduction to Prospectively Identify Patients for Adaptive Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics 94(4):p903, 2016. PMID: None.
34. Diffalha SAL, Walker R, Enderling H, Coppola D, Pimiento J, Mejia J. Tu1324 CD133 Protein expression as a biomarker for early detection of gastric cancer. None 150(4):s874-s875, 2016. PMID: None.
35. Walker R, Mejia J, Enderling H, Coppola D. H. pylori Infection Induces Early Expression of CD44 during the Progression of Gastric Cancer. None 96(Suppl 1):206A-206A, 2016. PMID: None.
36. Poleszczuk J, Prokopiou S, Robertson-Tessi M, Luddy KA, Moros E, Fishman M, Djeu JY, Enderling H. A systems biology approach to predict immunotherapy augmented abscopal effects. None 3(10):Supplement, 2015. PMID: None.
37. Prokopiou S, Poleszczuk J, Robertson-Tessi M, Luddy KA, Fishman M, Moros E, Djeu JY, Enderling H. Systems biology approach predicts the diagnostic value of T effector: T regulatory cell ratio in clinical response to combined radiation/immunotherapy of high-risk soft tissue sarcoma. None 3(10):Supplement, 2015. PMID: None.
38. Sasi SP, Song J, Park D, Enderling H, Gee H, Garrity B, Shtifman A, Yan X, Walsh KA, Natarajan M, Kishore R, Goukassian D. TNF-alpha and IL-1 alpha but not MCB-1 and Rantes increase significantly the formation of p-H2AX foci in naive BM-derived TNFR1/P55KO EPCs. None 55(Suppl 1):i122-3, 2014. PMID: None.
39. McDonald JT, Lee J, Rietman E, Lamont C, Enderling H, Peluso M, Hlatky L. Increased cytokine and chemokine expression in U87MG glioblastoma cells after large clinically relevant single doses of ionizing radiation. None 72(8):Supplement, 2012. PMID: None.
40. Muralidharan S, Sasi S, Yan X, Enderling H, Goukassian D. TNF-TNFR1/p55 or TNFR2/p75 Receptor-Ligand Interactions Inhibit Early and Increase Delayed Radio-Biological Bystander Responses in BM-Derived EPCs 111(4):Supplement, 2012. PMID: None.
41. Enderling H, Hlatky L, Hahnfeldt P. Cancer stem cells in solid tumors: Symmetric division, niche size, and invasive tumor morphology. None 71(8):Supplement, 2011. PMID: None.

Book Chapters

1. Enderling H. Cancer Stem Cell Kinetics. In: Encyclopedia of Systems Biology. None. Springer, 193-195, 2013.
2. Gao X, McDonald JT, Hlatky L, Enderling H. Cell-cell interactions in solid tumors: the role of cancer stem cells. In: New Challenges for Cancer Systems Biomedicine. None. Springer, None, 2012.
3. Enderling H, Vaidya JS. Mathematical Modelling of Breast Carcinogenesis, Treatment with Surgery and Radiotherapy and Local Recurrence. In: Selected Topics in Cancer Modeling - Genesis, Evolution, immune competition, and therapy. None. Birkhauser, 337, 2008.
4. Piotrowska MJ, Enderling H, an der Heiden U, Mackey MC. Mathematical Modeling of Stem Cells Related to Cancer. In: Cancer and Stem Cells. None. Nova Science Publishers, None, 2008.

Books (edited and written)

1. Enderling H, Almog N, Hlatky L. Systems Biology of Tumor Dormancy. Ed(s) None. Springer, 2012.